Table 3:

Association of sACE2 as continuous variable (ln transformed) and echocardiographic parameters at ARIC visit 5

Echocardiographic parameter	Model	Beta-coefficient	95% CI	p-value
Ln-LVEF	1	−0.02	−0.04, 0.002	0.08
	2	−0.02	−0.04, 0.002	0.07
	3	−0.004	−0.03, 0.02	0.68
Ln-LVMi	1	0.06	0.02, 0.09	0.001
	2	0.05	0.01, 0.08	0.009
	3	0.002	−0.03, 0.03	0.91
Ln-LAVi	1	0.08	0.03, 0.13	0.001
	2	0.06	0.01, 0.11	0.011
	3	0.01	−0.03, 0.05	0.73
Ln-septal e′	1	−0.04	−0.08, −0.01	0.02
	2	−0.03	−0.07, 0.01	0.10
	3	−0.01	−0.04, 0.03	0.76
Ln-septal E/e′	1	0.10	0.05, 0.15	<0.001
	2	0.07	0.02, 0.12	0.01
	3	0.02	−0.03, 0.07	0.47
GLS	1	0.61	0.21, 1.00	0.003
	2	0.53	0.14, 0.93	0.009
	3	0.16	−0.21, 0.54	0.39

Significant values in bold.

Increment in LVEF, LVMi, septal e′, septal E/e′ (log unit) and GLS (%) per log unit increase of sACE2, where sACE2 is the independent and hs-cTnI, hs-cTnT, or NT-proBNP dependent variable.

Model 1 is adjusted by age, sex, and race; model 2 is model 1 plus total cholesterol, HDL-C, current smoking, SBP, antihypertension medication use, diabetes status, lipid-lowering medication use, history of CVD (stroke, total CHD, and HF), and eGFR; model 3 is model 2 plus log hs-cTnI, log hs-cTnT, and log NT-proBNP.